Non-small cell lung cancer and Icotinib

1. T O M S C O R R E A G . K A R E N C A N O C . M E D I C I N E S T U D E N T S

2. A body has about a thousand, billion cells, which, when healthy, are indefinetely renewed. Some of these cells die every day and are replaced by new identical cells.

3. On some occassions a normal cell undergoes an alteration or errors due to numerous (exogenous) factors, such as:

4. These alterations or errors create a change in the DNA structure, leading to mistakes in the replication process.

5. There are endogenous causes that produce cancer; each person has hereditary factors (genes) that can lead to cancer. These genes are know as oncogenes.

6. When the cancerous cells proliferate at an abnormal rate, and there is a majority of cancerous (new) cells, the cellular mass is called a tumor.

7. The immune system protects us from various abnormal agents or cells. But in cancer, there are multiple factors that affect the function of the immune system: Tumoral cells reduce the expression of antigens in their membranes. Secretion of substances that reduce the function of the immune system. Tumors can grow without producing inflammation

8. It is a large group of diseases that are characterized by an abnormal growth of cell and the dissemination of these cells.

9. Carcinomas Sarcomas Lymphomas Leukemia

10. LUNG NON SMALL CELL CARCINOMA Is the most common lung cancer The principal cause is the exposure to tobacco smoke.

11. There are three forms: -adenocarcinoma -squamous cell carcinoma -large cell carcinoma

12. Adenocarcinoma: cells that line the alveoli Squamous cell carcinoma: in squamous cells Large cell carcinoma: begin in several types of large cells

13. Palliative care Surgery Chemotherapy Radiation therapy

14. USED PERSONALIZED BIOMARKERS TO MONITOR DISEASE PROGRESSION IN ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS THAT ARE TREATED WITH ICOTINIB

15. Icotinib Hydrochloride (BPI-2009H), or Icotinib, is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). EGFR is an oncogenic driver and patients with somatic mutations, particularly an exon 19 deletion or exon 21 L858R mutation, within the tyrosine kinase domain have activating mutations that lead to unchecked cell proliferation. Overexpression of EGFR causes inappropriate activation of the anti-apoptotic Ras signaling pathway, found in many different types of cancer. Icotinib is a quinazoline derivative that binds reversibly to the ATP-binding-site of the EGFR protein, preventing completion of the signal transduction cascade.

16. Icotinib en dosis de 150 mg 2 veces al da o 125mg 3 veces al da Seguido por un periodo de 3 dias Progreso de enfermedad Inexplicable toxicidad Rechazo al tratamiento Antes del tratamient o En tratamiento despus de un periodo de ayuno de 10 horas en la noche

17. Complejo IIRPCs ( inmunoinflammation- related protein complexes) 9 MUESTRA S 1 CONTRO L Mezcla aleatoria del plasma de 5 pacientes Patrones de enfermedad encontrados: a1,a2,a3,a4,a5,b1,b2,b3,b 4,b5,b6,d1,d2,d3,e1,e2 y e3 Complejo TRPC ( transferrin-related protein complex)

18. IIRPCs immuno inflammation-related protein complexes are associated with disease status. Epidermal growth factor receptor, the EGFR belongs to the family of tyrosine kinase receptors, EGFR plays a fundamental role in tumor development.

19. Immunoglobulin G1 -Interferes with the activation of the T-lymphocytes -Participate in the answer antigen A -To fix the complement -Joins to receptors FC in phagocytic cells IGA -This is in mucus -Is the first responder -Hinder the entrance of microorganism into the organism

20. Haptoglobin -This is fixed to the breakdown of hemoglobin. -Increases when the red blood cells are died. -recycle the components of the hemoglobin. Complement components -C3, C4: inflammation, increases in cancer. -C5: the first component of the complement of attack to membrane. -C7: component of attack to membrane.

21. Factor H -Protein regulatory of the complement Transferrin -Transports iron to plasma to the erythroblasts that are in marrow Apolipoprotein A1 -This are present in cholesterol HDL

22. Los patrones a, b y c fueron recogidos antes de iniciar el tratamiento. 19 pacientes con Patrn A 8 pacientes con Patrn B 4 pacientes con Patrn C

23. Complejo TRPC Comn en los 5 patrones ( a ,b ,c ,d y e) y el de mayor intensidad. Sus componentes fueron identificados usando espectrofotometra Ig-G1, Ig-A1, Haptoglobina, Complemento componente 3-4-5- 7, Factor de complemento H, Transferrina y Apolipoproteina A- 1.

24. Complejo TRPC No asociado con el patrn de IIRPCs, mutaciones en EGFR, dosis de medicamento, fumar, etapas, caractersticas histolgicas, edad y sexo. Valor de TRPC tuvo una estable expresin durante el tratamiento con icotinib Usado como referencia interna para la cuantificacin de IIRPCs

25. 7 Pacientes con patrn a cambiaron a patrn d, y 2 Pacientes con patrn b cambiaron a patrn e durante el tratamiento con icotinib, luego volvieron a su patrn original ya que generaron resistencia al medicamento, toxicidad o por el progreso de la enfermedad. Valle formado por el cambio de patrn.

26. PATIENTS

27. RESULTADOS

28. 1 paciente respuesta completa 8 respuesta parcial 19 estable 3 progreso

29. References What did they say? Agree with the article? Wang YY, Song GG, Wang YM, Qui L, Qin XZ, Liu H The measurement of the IIRPCs level is convenient using the optimized native polyacylamide gel. Elevated serum levels of circulating inmunoinflammati on-related protein complexes are associated with cancer and disease progression.

30. AUTHOR THEORY AGREE Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukos D, Murray S. O'Byrne K, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Storkel S. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K. Activation of the EGFR pathway has been implicated in NSCLC tumorigenesis, and EGFR has become an important target for the development of personalized therapy. However, acquired drug-resistance always occurred during the treatment. Recently, several molecular biomarkers such as EGFR expression and EGFR mutations have been Investigated as potential indicators of the treatment response to EGFRTKIs in NSCLC. Agree

31. 1. La actividad me pareci una buena experiencia para aprender a como presentar de una manera adecuada un seminario sobre un respectivo articulo. 2. La actividad sirvi mucho para practicar nuestro ingles y poder aprender nueva terminologa respecto al rea de biologa molecular y medicina

32. Conocer la actividad molecular de un tumor puede dar indicios de su comportamiento y formas de evitar su crecimiento. Una gran problemtica a la hora de realizar cualquier tipo de tratamiento es que el organismo genere resistencia.

33. REFERENCIAS Bioinformatics of Non Small Cell Lung Cancer and the Ras Proto-Oncogene By Amita Kashyap, D. Bujamma, Naresh Babu M Elevated serum levels of circulating immunoinflammation-related protein complexes are associated with cancer. Wang Y1, Song G, Wang Y, Qiu L, Qin X, Liu H, Li F, Wang X, Li F, Guo S, Zhang Y, Li Z. Elevated serum levels of circulating immunoinflammation-related protein complexes are associated with cancer. J. Proteome Res. J Proteome Res 2014 Feb 17;13(2):710-9. Epub 2013 Dec 17. Yanying Wang, Gaoguang Song, Yanmin Wang, Ling Qiu, Xuzhen Qin, Hui Liu, Fang Li, Xiaodong Wang,Fenjie Li, Shuai Guo, Yaping Zhang, Zhili Li Revista Habanera de Ciencias Mdicas versin On-line ISSN 1729-519X Rev haban cienc md v.9 n.2 Ciudad de La Habana abr.-jun. 2010 Introduccin a la inmunologa humana By Leonardo Fainboim, Jorge Geffner http://infoterbaru.zz.vc/info.php?q=cancer+research+uk+online+shop+online+shop+from+cancer+

34. MAPA CONCEPTUAL.

Non-small cell lung cancer and Icotinib

Health & Medicine

cancerous cells

tumoral cells

types of large cells

small cell carcinoma

normal cell

abnormal growth of cell

new identical cells

r e n c